⚠ Debt That Grows With Each PurchaseModerate threat

AbbVie (ABBV) — threat to the moat

AbbVie borrowed $8 billion in the first half of 2026 and is paying $10.9 billion in cash for Apogee.

AbbVie's debt rose in 2026 as it kept buying. It issued $7,991 million of long-term debt in the first half1, and agreed to buy Apogee Therapeutics for about $10.9 billion in cash, with closing expected in the third quarter2.

First half 2026 ($M)7,265Operating cash flow6,156Dividends paid7,991New long-term debtAbbVie Form 10-Q, Q2 2026
Dividends take most of the cash; deals are borrowed.

The company's cash commitments are large. It paid $6,156 million of dividends in the first half of 20263, and operating cash flow was $7,265 million4. Little is left for acquisitions without borrowing.

AbbVie's risk factors warn that its debt obligations could adversely affect its business5.

The cash flow is strong but committed. Operating cash flow was $19,030 million in 20256, against dividends of $11,657 million, capital spending of $1,214 million and other acquisitions and investments of $5,237 million7. Little was left over, which is why the Apogee purchase is being funded with borrowed money.

AbbVie's own guidance acknowledges the pattern. Its adjusted earnings forecast includes $0.14 of dilution from Apogee8, reflecting interest on the debt used to buy it and the loss of the target's cash. Each large purchase now arrives with a cost in borrowing as well as a cost in dilution.

Net debt after the Apogee closing is the number to watch. A figure well above $70 billion would mean the replacement strategy is being financed on credit.

References
  1. ReportedIt issued $7,991 million of long-term debt in the first half, and agreed to buy Apogee Therapeutics for about $10.9 billion in cash, with closing expected in the third quarter.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  2. ReportedIt issued $7,991 million of long-term debt in the first half, and agreed to buy Apogee Therapeutics for about $10.9 billion in cash, with closing expected in the third quarter.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  3. ReportedIt paid $6,156 million of dividends in the first half of 2026, and operating cash flow was $7,265 million.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  4. ReportedIt paid $6,156 million of dividends in the first half of 2026, and operating cash flow was $7,265 million.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  5. ReportedAbbVie's risk factors warn that its debt obligations could adversely affect its business.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  6. ReportedOperating cash flow was $19,030 million in 2025, against dividends of $11,657 million, capital spending of $1,214 million and other acquisitions and investments of $5,237 million.
    AbbVie Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions and contingent consideration. — FY2025 · publ. 20 February 2026 · source ↗
  7. ReportedOperating cash flow was $19,030 million in 2025, against dividends of $11,657 million, capital spending of $1,214 million and other acquisitions and investments of $5,237 million.
    AbbVie Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions and contingent consideration. — FY2025 · publ. 20 February 2026 · source ↗
  8. ReportedIts adjusted earnings forecast includes $0.14 of dilution from Apogee, reflecting interest on the debt used to buy it and the loss of the target's cash.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
Sources
Generated September 25, 2026